Biotech News
Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights
Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach AI-driven AP3 platform was used for profiling against approved JAK inhibitors to identify recently acquired ACR-525, a Phase 2-ready,
